Table 2. Factors affecting pathological lymph node involvement after neoadjuvant chemotherapy.
| pN | p-value | |||
|---|---|---|---|---|
| Negative | Positive | |||
| Menopausal status | 0.534† | |||
| Premenopause | 27 (45.8%) | 32 (54.2%) | ||
| Perimenopause | 14 (51.8%) | 13 (48.2%) | ||
| Postmenopause | 60 (41.4%) | 85 (58.6%) | ||
| Grade | 0.001† | |||
| Grade 1 | 2 (11.8%) | 15 (88.2%) | ||
| Grade 2 | 63 (40.9%) | 91 (59.1%) | ||
| Grade 3 | 36 (60.0%) | 24 (40.0%) | ||
| HER 2 | <0.001* | |||
| Negative | 32 (24.6%) | 98 (75.4%) | ||
| Positive | 69 (68.3%) | 32 (31.7%) | ||
| Molecular subtype | <0.001* | |||
| Luminal A | 1 (4.6%) | 21 (95.4%) | ||
| Luminal B | 51 (36.9%) | 87 (63.1%) | ||
| HER 2+ | 35 (77.7%) | 10 (22.3%) | ||
| Triple- | 14 (53.8%) | 12 (46.2%) | ||
| PET axillary involvement | <0.001* | |||
| Negative involvement | 92 (65.7%) | 48 (34.3%) | ||
| Positive involvement | 8 (8.7%) | 83 (91.3%) | ||
*
Chi-square test.
†
Mann-Whitney U test.